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ABSTRACT
The constant presence of the viral genome in Epstein-Barr virus (EBV)-associated 
gastric cancers (EBVaGCs) suggests the applicability of novel EBV-targeted therapies. 
The antiviral nucleoside drug, ganciclovir (GCV), is effective only in the context of the 
viral lytic cycle in the presence of EBV-encoded thymidine kinase (TK)/protein kinase 
(PK) expression. In this study, screening of the Johns Hopkins Drug Library identified 
gemcitabine as a candidate for combination treatment with GCV. Pharmacological 
induction of EBV-TK or PK in EBVaGC-originated tumor cells were used to study 
combination treatment with GCV in vitro and in vivo. Gemcitabine was found to be a 
lytic inducer via activation of the ataxia telangiectasia-mutated (ATM)/p53 genotoxic 
stress pathway in EBVaGC. Using an EBVaGC mouse model and a [125I] fialuridine 
(FIAU)-based lytic activation imaging system, we evaluated gemcitabine-induced 
lytic activation in an in vivo system and confirmed the efficacy of gemcitabine-GCV 
combination treatment. This viral enzyme-targeted anti-tumor strategy may provide 
a new therapeutic approach for EBVaGCs.
INTRODUCTION
Epstein-Barr virus (EBV) is a double-stranded DNA 
human gamma herpes virus that establishes a persistent 
infection in over 90% of individuals. Most infections 
are self-limiting, but some cases are associated with the 
development of malignancies of lymphoid or epithelial 
origin [1]. EBV-associated gastric carcinomas (EBVaGCs) 
make up about 9% of all stomach cancers [2]. The presence 
of EBV in lymphoma or leukemia is known to confer a 
poorer prognosis [3–5]; however, a recent retrospective 
study revealed that EBV positivity in gastric cancer is 
associated with lower mortality and provides an additional 
prognostic indicator [2]. In addition to the conventional 
chemotherapy and surgical treatments, many EBV-
positive malignancy experimental treatments are aimed at 
targeting the EBV episome, inhibiting EBV-transforming 
proteins, EBV-dependent expression of cellular toxins, 
and modulation of immune responses with EBV-specific 
cytotoxic T lymphocytes (CTL) [6, 7]. Recent studies 
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based on the concept of selective destruction of tumor 
cells have suggested that the induction of lytic activation 
in EBV-associated tumors and combination treatment 
with the antiviral agent ganciclovir (GCV) represents a 
potential anti-cancer treatment modality [7–10].
GCV is efficiently phosphorylated and activated 
by the viral thymidine kinase (TK) or protein kinase 
(PK) [11, 12]. Phosphorylated GCV interferes with 
subsequent cellular DNA synthesis, resulting in apoptotic 
cell death [13, 14]. Herpes Simplex Virus (HSV)-TK/
GCV cytotoxic gene therapy is effective in vitro, but the 
gene delivery of HSV-TK is problematic in vivo [15]. 
Endogenous EBV-TK or EBV-PK (referred to as EBV-
TK/PK) induced during lytic activation in EBV-associated 
tumors, however, may provide an alternative strategy [16]. 
Therefore, identification of the reagents that can induce 
lytic activation in EBV-associated tumors is critical.
Several pharmacological agents are known to induce 
lytic activation via the endoplasmic reticulum (ER) or 
genotoxic stress response in EBV-infected cells [8, 9, 
17–19]. We screened the Johns Hopkins Drug Library 
(JHDL) to find clinically applicable new drugs as a drug 
repositioning approach [20]. From this screen, we selected 
gemcitabine (2, 2-difluorodeoxycytidine, dFdC; Gemzar), 
which has been used in various cancer therapeutic 
regimens [21–24]. Gemcitabine has been shown to be a 
lytic inducer with therapeutic potential in EBV-positive B 
cell lymphoma cell lines and nasopharyngeal carcinoma 
cell lines [8, 25], but this drug has not been examined with 
respect to the precise mechanism of lytic activation in the 
context of EBVaGC.
In this study, we determined the dose of gemcitabine 
required for the induction of EBV lytic activation and 
explored the mechanism of this drug. Moreover, we 
determined whether gemcitabine-GCV combination 
treatment was effective in inducing cell death in SNU-719 
cells, a gastric cancer cell line that is naturally infected 
with EBV. We established an EBVaGC-bearing mouse 
model and [125I]-1-(2-fluoro-2-deoxy-D-arabinofuranosyl)-
5-iodouracil (FIAU)-based molecular imaging to evaluate 
gemcitabine-induced lytic activation and gemcitabine-
GCV combination treatment in vivo. The effectiveness of 
combination therapy was confirmed in vivo by this mouse 
model and imaging system.
RESULTS
The expression of EBV-TK/PK during 
gemcitabine-induced lytic activation in 
SNU-719 cells
We sought to identify new chemical reagents 
that could induce lytic activation in EBVaGCs by high-
throughput screening of JHDL using EBV BZLF1 
promoter-transfected human gastric carcinoma (AGS) 
cells [20]. From 2,687 drugs, we got 188 candidates 
showing significantly increased luciferase activity when 
compared with control (Supplementary Table S1). 
Validation experiments were performed on the upper 15% 
(29 drugs, bold lettering in Supplementary Table S1). 
Gemcitabine was identified as an ideal candidate for 
further evaluation. Treatment of the EBVaGC cell line 
SNU-719 and the EBV-negative gastric cancer (EBVnGC) 
cell line MKN-74 with gemcitabine as scheduled in 
Figure 1A revealed that the EBV immediate early (IE) 
lytic protein Zta was induced in SNU-719 cells even at 
a low dose (5 ng/ml; Figure 1B). Zta protein expression 
was confirmed by immunofluorescence microscopy (IFA) 
(Figure 1C). Moreover, this effect was observed beginning 
48 h after gemcitabine treatment (Supplementary Figure 
S1A and S1B). To determine whether the low dose of 
gemcitabine induces other lytic genes, we performed 
RT-PCR to evaluate the induction of BGLF4 (EBV-PK) 
and BXLF1 (EBV-TK). These genes exhibited a similar 
expression pattern to that of BZLF1, which encodes the 
Zta (Figure 1D). Additionally, a component of virion, 
gp350, was detected only in lytic activation-induced SNU-
719 cells (Figure 1E).
The ER or genotoxic stress response is associated 
with EBV lytic activation [18, 26]. Moreover, the ataxia 
telangiectasia-mutated (ATM) kinase/p53 pathway is 
activated during genotoxic stress-induced EBV lytic 
activation [18]. We first screened for the involvement of 
the ER stress response during gemcitabine-induced lytic 
activation, but C/EBP-homologous protein (CHOP) and 
glucose-regulated protein-78 (GRP78), which are known 
ER stress markers, exhibited no differences between 
SNU-719 and MKN-74 cells following gemcitabine 
treatment (Supplementary Figure S2). We next evaluated 
lytic activation in the context of ATM/p53 activation. 
SNU-719 cells have wild-type TP53 [27], yielding an 
intact ATM/p53 pathway. Serine 1981 of ATM was 
phosphorylated 3 h after gemcitabine treatment, and serine 
15 of p53 was phosphorylated subsequently (Figure 1F). 
Phosphorylated p53 was decreased following treatment 
with the ATM inhibitor KU55933 (Figure 1G), which may 
have suppressed Zta expression as previously reported 
[18]. To further evaluate the involvement of the ATM/
p53 pathway in lytic activation, we performed siRNA-
based knock-down experiments. Phosphorylation of p53 
was decreased by si-ATM, resulting in a decrease of Zta 
protein expression (Figure 1H). Moreover, this finding 
was confirmed by si-TP53 (Figure 1I). Collectively, these 
results suggest that gemcitabine induces lytic activation 
via the ATM/p53-mediated genotoxic stress pathway in 
SNU-719 cells.
Gemcitabine confers GCV susceptibility on 
EBVaGC cells
To confirm that the induction of EBV-TK/PK was 
applicable to this combination treatment, enzymatic activity 
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Figure 1: Expression of EBV-TK/PK during gemcitabine-induced lytic activation via ATM/p53 genotoxic stress 
pathway in EBVaGC cells. A. Administration schedule of gemcitabine. EBVaGC cells (SNU-719) or EBVnGC cells (MKN-74) were 
treated with gemcitabine (0-80 ng/ml) for 24 h and were cultured for another 2 days. Zta expression was evaluated by western blot B. and 
IFA C.  Blue, DAPI; Red, Zta. D. RT-PCR for BZLF1, BGLF4, and BXLF1 was performed on gemcitabine (0–10 ng/ml)-treated SNU-719 
cells. RT (−) lane is a negative control to determine contamination by EBV genomic DNA. E. gp350 was visualized by IFA in 10 ng/ml 
gemcitabine-treated SNU-719 cells. Blue, DAPI; Red, gp350. F. Changes in phosphorylated ATM (pSer 1981) and p53 (pSer 15) during 
gemcitabine treatment were evaluated by western blot. G–I. ATM inhibitor (KU55933) was treated after 24 h-gemcitabine treatment, while 
si-ATM and si-TP53 were transfected before gemcitabine treatment. Inhibition of lytic activation by KU55933, si-ATM, or si-TP53 was 
evaluated by changes in Zta, ATM, phosphorylated ATM, p53, and phosphorylated p53 using western blot. β-actin or GAPDH was used as 
loading controls.
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was measured using the radio-isotope labeled-nucleoside 
analogue, [125I] FIAU [28]. Cellular accumulation of 
[125I] FIAU showed a positive correlation with the dose of 
gemcitabine in SNU-719 cells but not in MKN-74 cells 
(Figure 2A).
We examined the concentration of gemcitabine 
that induced lytic activation while minimizing cell death 
as gemcitabine is currently used as a chemotherapeutic 
drug in various kinds of cancers [21–24]. The inhibition 
of cell proliferation by 50% (IC50) for MKN-74 cells 
was 2.2–3.8 ng/ml, which is similar to the concentration 
previously reported [22], while that of SNU-719 cells 
(8.4–16.8 ng/ml) was slightly higher (Figure 2B). Thus, 
the induction of lytic activation in SNU-719 cells by 5 
ng/ml gemcitabine occurred at a level below the IC50. 
To establish a combination treatment protocol with 
gemcitabine and GCV, we first treated cells with GCV 
alone. Little difference in the response of SNU-719 and 
MKN-74 cells to GCV treatment was noted, and GCV had 
little influence on both cell types even at a relatively high 
concentration (100 μg/ml; Figure 2C).
The cytotoxicity of the combination treatment was 
evaluated under an optimized schedule as described in 
Figure 2D. This schedule was based on the toxicity and 
short half-life (8–17 min) of gemcitabine [29]. Gemcitabine 
conferred cytotoxicity on GCV in SNU719 cells but 
not in MKN-74 cells (Figure 2E and 2F). GCV worked 
more efficiently in concert with the low concentration of 
gemcitabine. That is, the decrease in cell survival was 
more profound at 0.1–10 ng/ml than at 10–100 ng/ml. 
GCV did not exert an additional effect at gemcitabine 
concentrations of 1 μg/ml. GCV induced maximum 
efficacy when 100 μg/ml GCV was combined with 
lytic activation-inducible concentrations (1–100 ng/ml) 
of gemcitabine in vitro. Taken together, a low dose 
of gemcitabine combined with GCV is an efficacious 
combination treatment option in these cells.
Establishment of a lytic activation-inducible 
SNU-719 cell-implanted NOD-SCID 
mouse model
An EBVaGC animal model system is indispensable 
for in vivo evaluation of gemcitabine-GCV combination 
treatment. We therefore developed a mouse model for 
this purpose using NOD-SCID. SNU-719 cell-implanted 
mice developed measurable tumors in 40–45 days after 
implantation. Although Matrigel did not affect cell 
viability, Matrigel-based SNU-719 tumors were more 
suitable for in vivo experiments than PBS-based inocula 
because of improved tumor establishment efficiency and 
consistency of tumor size (Supplementary Figure S3A). 
Isolated tumors exhibited necrotic regions as reported 
previously (Supplementary Figure S3B) [30, 31]. 
Moreover, tumors kept the phenotypes of SNU-719 cells 
and EBV genome, which was verified by flow cytometry 
(Supplementary Figure S3C) and EBV-encoded small 
RNAs (EBER)-in situ hybridization (ISH) (Supplementary 
Figure S3D).
Next, we tested whether gemcitabine induced 
functional EBV lytic proteins in this mouse model. The 
gemcitabine concentration commonly used in cancer 
therapy for human is 20–60 μM (i.e., 5.2–15.6 μg/ml) 
in plasma, and such levels are achieved by infusion of 
drug at a dose of 1,000–1,200 mg/m2 [29]. For our mouse 
model, gemcitabine was used with a much lower dose than 
used in cancer therapy, and induced Zta in SNU-719 cell-
implanted tumors (referred to as SNU-719 tumors) in a 
dose-dependent manner (Figure 3A). BGLF4 and BXLF1 
were also induced in SNU-719 tumors (Figure 3B) as 
observed in the in vitro system. We used [125I] FIAU-based 
single-photon emission computed tomography (SPECT) 
planar imaging to confirm the induction of functional 
EBV-TK/PK in SNU-719 tumors. The intensity of the 
[125I] FIAU signal showed a positive correlation with the 
dose of gemcitabine, whereas this signal was not detected 
in MKN-74 cell-implanted tumors (referred to as MKN-
74 tumors) (Figure 3C). This result was confirmed by 
imaging of isolated tumors (Figure 3D).
Efficient gemcitabine-GCV combination 
treatment in the EBVaGC mouse model
The ability of gemcitabine to induce EBV-TK/PK 
in the mouse model system led us to test combination 
treatment with GCV. Approximately 1 × 107 SNU-
719 cells or 2 × 106 MKN-74 cells were engrafted 
subcutaneously in the right flank of NOD-SCID mice. 
When the tumors reached approximately 1,000 mm3, the 
mice were treated with the indicated dose of gemcitabine 
or GCV as scheduled (Figure 4A). A dose of 10 mg/kg 
gemcitabine and 25 mg/kg GCV had little influence on 
tumor growth in MKN-74 cell-engrafted mice; however, 
the same dose of gemcitabine, alone or in combination 
with GCV, resulted in gradual regression of tumors until 
the tumors were no longer palpable in SNU-719 cell-
engrafted mice (Figure 4B and 4C). Mice treated with 
gemcitabine only and the gemcitabine-GCV combination 
lost body weight severely, which made the experiment 
discontinue after 3 cycles in accordance with IACUC 
guidelines (Figure 4D). Therefore, we sought to identify a 
gemcitabine concentration that produced synergism with 
GCV without inducing adverse effects. The combination 
of 0.5 mg/kg gemcitabine and 25 mg/kg GCV with 
the same schedule suppressed the growth of tumors 
significantly (Figure 5A), accompanied by significant but 
tolerable body weight loss (Figure 5B).
DISCUSSION
The recent remarkable progress in cancer research 
has produced new target-oriented drugs and treatment 
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Figure 2: Gemcitabine confers GCV susceptibility on EBVaGC cells. A. Gemcitabine-treated SNU-719 or MKN-74 cells were 
incubated with 1 μCi/2 ml [125I] FIAU for 4 h. The radioactivity of harvested cells was determined by a γ-counter. SNU-719 and MKN-
74 cells were treated with either B. gemcitabine or C. GCV for 4 days. Then the viable cells were determined by the CCK-8 assay. 
D. Administration schedule of gemcitabine and GCV. Dose response of E. SNU-719 cells and F. MKN-74 cells to gemcitabine. Serially 
diluted gemcitabine and indicated doses of GCV were added as administration schedule. The 95% confidence intervals of the slopes, which 
were determined using best-fit four-parameter regression, are shown. The statistical analysis was performed between Gem only and Gem + 
100 ug/ml GCV. Values represent means ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001.
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Figure 3: Establishment of a lytic activation-inducible EBVaGC mouse model. A. Western blot and B. RT-PCR of EBV lytic 
genes in isolated tumors from gemcitabine-treated mice. GAPDH or β-actin was used as loading controls. C–D. Tumor cell-engrafted mice 
were injected with gemcitabine (0.1, 1, or 10 mg/kg) and administrated 200 μ Ci [125I] FIAU in 24 h after drug injection. The mice (C) or 
isolated tumors (D) were imaged using SPECT. Color bar indicates the range of [125I] FIAU uptake as a percentage. T, Thyroid.
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Figure 4: Gemcitabine-GCV combination treatment in EBVaGC cell-implanted mice. A. Gemcitabine/GCV administration. 
Tumor volume in mice implanted with B. SNU-719 or C. MKN-74 cells and injected intraperitoneally with 10 mg/kg gemcitabine, 
25 mg/kg GCV, or both according to the schedule shown in above. Body weight in D. SNU-719- or E. MKN-74-implanted mice injected 
intraperitoneally with 10 mg/kg gemcitabine, 25 mg/kg GCV, or both according to the schedule shown above. Tumor mass and body weight 
were measured before every gemcitabine injection. Each data point reflects observations from five mice. Both values were calculated as the 
percentage of the initial value for each mouse. Values represent means ± SEM.
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strategies [32]. Three decades ago, virus-targeted 
therapies were tried for the treatment of virus-associated 
cancers [33]. An anti-viral prodrug, GCV, selectively 
phosphorylated by HSV-TK, was suggested for the 
treatment of virus-associated cancers [7]. EBV encodes 
TK and PK enzymes that each have the capacity to 
phosphorylate GCV and are only expressed during lytic 
activation. Therefore, chemicals that act as lytic inducers 
have been sought to facilitate treatment with GCV. 
Epigenetic modifying agents (5-azacytidine, trichostatin 
A, sodium butyrate, and valproic acid) and some anti-
cancer drugs (5-fluorouracil [5-FU], cis-platinum, and 
taxol) induce lytic activation in EBV-positive cell lines 
that originate from various tumors [8, 9, 17, 19, 34, 35]. 
The effectiveness of these reagents differs among different 
cell types. For instance, 5-FU and cis-platinum efficiently 
induce lytic activation in EBV-positive epithelial cell 
tumors but not in lymphoblastoid cell lines (LCLs) or 
B cell tumors. These differences make it difficult to 
generalize the outcome of EBV-lytic induction treatments, 
and therefore only a few clinical trials of these agents have 
been performed [36, 37]. Recently, EBV lytic activation 
was reported to be induced by the ER or genotoxic 
stress response. Moreover, the ATM/p53 pathway that is 
activated during the genotoxic stress response directly 
influences Zta induction [18, 26]. The different sensitivity 
of lytic inducers among cell types may originate from 
differences in the underlying molecular mechanisms 
during lytic activation.
In this study, we attempted to find new drugs that 
induce lytic activation more efficiently in EBVaGCs 
and do not affect healthy cells and tissues by screening 
JHDL with BZLF1 promoter-transfected AGS cells. This 
library consists of drugs that are already used in patients 
and approved for safety and toxicity, allowing a bypass 
of phase I/II clinical trials [38, 39]. Gemcitabine was 
selected and was confirmed as a lytic inducer by induction 
of lytic gene expression and EBV-TK/PK activity in 
EBVaGC SNU-719 cells. Moreover, we observed that an 
extremely low dose (5 ng/ml) of gemcitabine induced Zta 
in SNU-719 cells compared to the dose required in LCLs 
or B cell lines (1 μg/ml) [8], which was checked using 
our optimized schedule (Supplementary Figure S1C). The 
dose discrepancy between EBVaGC-derived cells and B 
cell lymphoma-derived cells requires further evaluation 
with respect to molecular mechanisms.
Furthermore, gemcitabine-induced lytic activation 
was evaluated to determine whether the ER or genotoxic 
stress pathway was involved. The ATM inhibitor 
KU55933, si-ATM, or si-TP53 treatment induced a 
decrease in Zta protein expression. Since the duration of 
ATM inhibitor activity is very short, suppression by the 
ATM inhibitor was relatively weaker than that of si-ATM. 
Most Zta expression was diminished by si-ATM and si-
TP53. Therefore, the ATM/p53 pathway may be a key 
regulator involved in lytic activation by gemcitabine. 
For this reason, p53 may be applicable as a biomarker to 
determine whether an EBVaGC patient is a candidate for 
gemcitabine-GCV combination treatment. TP53 mutation 
is frequently observed in gastric cancers of various types, 
but is actually rarely observed in EBVaGCs [40, 41]. 
Moreover, the stability of p53 is also regulated by the 
interaction with EBNA1 [42]. Thus, the status of p53 may 
determine the responsiveness of gemcitabine-induced lytic 
activation, although this notion requires further evaluation.
The final goal of this study was to apply GCV to 
EBV-TK/PK-induced EBVaGC cells. The enzymatic 
activity of gemcitabine-induced EBV-TK/PK was verified 
by showing a positive correlation between gemcitabine 
concentration and the accumulation of [125I] FIAU. The 
Figure 5: Optimization of gemcitabine-GCV combination treatment in EBVaGC mice. Mice were injected with 0.5 mg/
kg gemcitabine only or 25 mg/kg GCV in combination with 0.5 mg/kg gemcitabine as scheduled in Figure 4A. Tumor mass and body 
weight were measured before every gemcitabine injection. Each data point reflects observations obtained from five mice. Both values were 
calculated as the percentage of the initial value for each mouse. Values represent means ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001
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accumulation of [125I] FIAU in the gemcitabine-untreated 
SNU-719 cells may be due to abortive lytic activation as 
discussed previously [8]. There are some data supporting 
abortive lytic activation in this study. Despite the absence 
of gemcitabine, BZLF1 was observed by RT-PCR in SNU-
719 cells and in mouse-implanted SNU-719 cells. Even 
with an extremely low dose of gemcitabine, the survival 
of SNU-719 cells was significantly decreased by GCV 
treatment, and this is consistent with a previous report [8]. 
Despite these observations, it remains unclear whether 
these observations are a direct read-out of abortive lytic 
activation.
We also evaluated the toxicity of gemcitabine and 
GCV respectively, and then examined the effects of an 
in vitro combination treatment. Gemcitabine exhibited a 
narrow safety window in SNU-719 and MKN-74 cells, 
but GCV was safe at a relatively high concentration 
(100 μg/ml). Synergistic effects of combination treatment 
were observed with a range of 0.1–100 ng/ml, as reported 
previously [8, 19]. The concentration of gemcitabine was 
the most important factor for efficacy of the combination 
treatment. In a previous report, the contribution of GCV-
induced cytotoxicity may have been underestimated 
due to the high dose of gemcitabine (1 μg/ml) [8], as 
at this dose, we observed no beneficial outcomes in 
combination with GCV. To overcome this problem, we 
utilized multiple treatments of low-dose gemcitabine. 
Gemcitabine-GCV combination treatment has previously 
been reported as a treatment for cancers, albeit via a 
completely different mechanism [15]. Gemcitabine was 
utilized as a ribonucleotide reductase inhibitor, which 
reduces endogenous dGTP to increase the incorpora-
tion of phosphorylated GCV into DNA. Moreover, 
gemcitabine is also known to increase the sensitivity 
of bystander cytotoxicity, although the concentration of 
gemcitabine needed for such effects (10 μM or 2.6 μg/ml) 
is 100 times higher than the concentration used in our 
studies.
To date, only a few reports have described mouse 
models bearing EBVaGC-originated cell lines due to the 
rareness of EBV-naturally infected GC cell lines and the 
limited establishment of tumors in immune competent 
animals [19, 43] or nude mice [31]. In this study, we 
established a lytic activation-inducible EBVaGC mouse 
model using NOD-SCID mouse, and furthermore, [125I] 
FIAU-based EBV lytic activation monitoring system. 
Then, we evaluated a gemcitabine-GCV combination 
treatment with this EBVaGC mouse model. In the initial 
evaluation, gemcitabine was injected once a week, but 
the regression of tumor growth was slow in spite of the 
relatively high dose (data not shown). Following the 
Ghosh et al. protocol for butyrate [44], we modified 
the dosing schedule to consider gemcitabine toxicity and 
rapid turnover rate, and observed the efficient induction 
of lytic activation with a multiple low dose schedule. As 
a result, we identified a combination treatment of 0.5 
mg/kg gemcitabine and 25 mg/kg GCV that suppressed 
tumor growth more effectively than gemcitabine alone 
without adverse effects. To increase the efficacy of 
gemcitabine-GCV combination treatment, we would 
consider establishing new EBVaGC model using the 
nude mice due to the high sensitivity for drug-induced 
apoptosis of NOD-SCID mice. Furthermore, recently, 
it was reported that the combination treatment with 
gemcitabine, valproic acid, and GCV was efficient in 
EBV-positive refractory nasopharyngeal carcinoma 
patients [25]. Thus, additional combination with valproic 
acid could be considered.
In summary, gemcitabine was selected from a screen 
of JHDL for its ability to induce EBV lytic activation in 
vitro and in vivo in an EBVaGC cell line, SNU-719. ATM/
p53 genotoxic stress is a key regulator of gemcitabine-
induced lytic activation. We also developed a lytic 
activation-inducible EBVaGC mouse model to evaluate 
the efficacy of gemcitabine-GCV combination treatment 
in vivo in concert with an imaging system for evaluating 
lytic activation. EBV lytic activation-based GCV 
combination therapy showed promising results in our 
EBVaGC mouse model. To apply these results to EBVaGC 
patients, gemcitabine-induced lytic activation must be 
generalized using new patient-derived EBVaGC cell lines 
and their xenograft-bearing mouse models.
MATERIALS AND METHODS
Cell lines
The SNU-719 and MKN-74 cell lines, which were 
obtained from the Korea Cell Line Bank (Seoul, Korea), 
are EBV-positive and EBV-negative gastric carcinoma 
cell lines, respectively. Cells were cultured in RPMI-1640 
supplemented with 10% heat-inactivated FBS (Hyclone, 
Tauranga, New Zealand) at 37ºC in a humidified CO2 
incubator.
Chemical reagents and siRNAs
Gemcitabine (Eli Lilly, Indianapolis, IN, USA), 
ganciclovir (Sigma-Aldrich, St Louis, MO, USA), 
phorbol 12-myristate 13-acetate (PMA, 20 ng/ml; Sigma-
Aldrich), and ataxia telangiectasia-mutated (ATM) 
kinase inhibitor (KU55933, 10 μM; Calbiochem, San 
Diego, CA, USA) were used. The siRNAs targeting ATM 
(NM_000051) and TP53 (NM_000546) were designed 
and generated as Supplementary Table S2 (Integrated 
DNA Technologies; IDT, Coralville, IA, USA). The 
target sequences of the selected siRNAs are as follows: 
ATM, AGCUAUCAGAGAAGCUAAUAAAUTA and 
TP53, CCACCAUCCACUACAACUACA UGTG. The 
siRNAs were transfected using Lipofectamine RNAiMAX 
(Invitrogen, Carlsbad, CA, USA) according to the 
manufacturer’s protocol.
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Induction and inhibition of EBV lytic activation 
in SNU-719 cells
Cells were treated with the indicated doses of 
gemcitabine (0–80 ng/ml) as shown in Figure 1A. Briefly, 
Cells were incubated for 24 h, then washed with PBS, 
followed by additional culture for 48 h. To suppress 
lytic activation, cells were treated with ATM inhibitor 
(KU55933) for 1 h after gemcitabine treatment.
Western blot analysis
Cells or tumors were lysed with RIPA buffer (50 
mM Tris-Cl [pH 7.5], 150 mM NaCl, 1% NP-40, 0.5% 
sodium deoxycholate, 0.1% SDS). Samples were separated 
on a 10% acrylamide gel and transferred to a 0.45 μm 
nitrocellulose membrane (Bio-Rad, Hercules, CA, USA). 
Membranes were blocked in TBS containing 5% non-
fat milk and 0.05% Tween 20 solution and incubated 
with primary antibody (Ab). The following antibodies 
were used for western blot: anti-Zta (Argene, Verniolle, 
France), anti-p53 (Novocastra, Buffalo Grove, IL, USA), 
anti-p53 pSer15 (Cell Signaling Technology, Beverly, MA, 
USA), anti-ATM (Cell Signaling Technology), anti-ATM 
pSer1981 (Cell Signaling Technology), and anti-β-actin 
(Sigma-Aldrich)
Immunofluorescence assay
Cells were fixed in cold 4% paraformaldehyde for 
30 minute and blocked with 10% normal donkey serum 
(Jackson ImmunoResearch, West Grove, PA, USA) for 
1 h at room temperature. Cells were stained with anti-Zta 
or anti-gp350 Ab (gift from Prof. Song) and Rhodamine 
Red-X-AffiniPure donkey anti-mouse IgG (H+L) (Jackson 
ImmunoResearch). and then visualized by LSM 700 
confocal microscopy (Cal Zeiss, Oberkochen, Germany). 
In addition, 4, 6-diamidino-2-phenylindole (DAPI; Vector 
Laboratories, Burlingame, CA, USA) staining was also 
performed to visualize cell nuclei.
RT-PCR
RNA was isolated from cell pellets or tumor 
tissues using the RNeasy Mini kit and RNase-free 
DNase (QIAGEN, Valencia, CA, USA) following the 
manufacturer’s instructions. The cDNA was synthesized 
using 5 μg total RNA, SuperScript III reverse transcriptase 
(Invitrogen) and random hexamers. PCR was performed 
to evaluate EBV lytic gene expression using the specific 
primers: BZLF1, 5′-ACC AAG CCG GGG GAG AAG 
CA-3′ and 5′-CCA GGC TTG GGC ACA TCT GC-3′; 
BGLF4, 5′-CGC TCG GCT ACT CGC TGC TC-3′ and 
5′-CGG AGG AAG CGG GCA AAC GT-3′; BXLF1, 5′-
TTA CCC TGC CCA GGG GAG CC-3′ and 5′-GTC ATC 
GAG CCC AAG GCC GG-3′; GAPDH, 5′-GAT GGC 
ATG GAC TGT GGT CA-3′ and 5′-GCA ATG CCT CCT 
GCA CCA CC-3′. GAPDH expression was used as an 
internal control. RT (-) PCR was performed to rule out 
contamination by EBV genomic DNA.
[125I] FIAU cellular uptake assay
Cells, which were induced into lytic activation as 
described, were incubated with 1 μCi/2 ml [125I] FIAU at 
37ºC for 4 h. Then cells were washed and harvested with 
200 μl trypsin-EDTA (0.25%, Thermo Fisher Scientific 
Inc., Rockford, IL, USA), followed by addition of 400 μl 
PBS. The radioactivity was measured using a γ-counter 
(Perkin Elmer, Waltham, MA, USA). The accumulation of 
[125I] FIAU was calculated as the percentage of the input 
dose added to the medium (%AD) [45].
Cell viability assay
Cell viability was analyzed using the Cell Counting 
Kit-8 (CCK-8; Dojindo Lab, Kumamoto, Japan). SNU-719 
(3 × 103 cells/100 μl) and MKN-74 (2 × 103 cells/100 μl) 
cells were plated in 96-well plates and incubated at 37ºC in 
5% CO2 overnight. Then, the cells were treated as described 
in Figure 2D. Then, 10 μl CCK-8 solut ion (2-[2-methoxy-
4-nitrophenyl]-3-[4-nitrophenyl]-5-[2, 4-disulfophenyl]-
2H-tetrazolium) was added to each well. The plates were 
incubated at 37ºC for 3 h, and the absorbance at 450 nm 
was measured using a microplate reader (Perkin Elmer, 
Waltham, MA, USA).
Generating EBV-positive or -negative GC cell 
line-implanted mice
All mice were maintained under specific pathogen-
free conditions, and the experiments involving animals 
were approved by the Institutional Animal Care and Use 
Committees (IACUC) at Yonsei University College of 
Medicine (2012-0263). Six to seven-week-old female 
NOD-SCID mice (Korea Research Institute of Bioscience 
and Biotechnology, Daejeon, Korea) were used for all 
experiments. SNU-719 or MKN-74 cells were suspended 
in a 200 μl solution containing 100 μl Matrigel (BD 
Biosciences, Franklin Lakes, NJ, USA) and 100 μl PBS 
and then injected subcutaneously into the right or left flank 
of mice. Tumor size was measured approximately every 
third day with calipers, and tumor volume was calculated 
as l × w2 (l: long axis, w: width) [15]. Approximately 6 
or 4 weeks after implantation of SNU-719 or MKN-74 
cells, respectively, mice carrying tumors that reached 
a volume of approximately 1,000 mm3 , were used for 
in vivo experiments and imaging.
Molecular imaging of in vivo lytic activation
When the tumor size reached approximately 1,000 
mm3, 200 μCi [125I] FIAU was administered to each tumor-
carrying mouse through the tail vein. The mice were 
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imaged by [125I] FIAU-based SPECT planar imaging as 
previously described [45]. Briefly, the mice were placed in 
a posterior position on a warm-bed and anesthetized with 
2% isoflurane (Choongwae, Seoul, Korea) before injection 
of [125I] FIAU and 1.5% isoflurane during imaging. For 
thyroid-blocked images, 1 mg sodium perchlorate (Sigma-
Aldrich) was injected intraperitoneally into the mice 
before injection of [125I] FIAU.
Statistical analysis
Statistical analysis was performed with unpaired 
Student’s t-tests. All in vitro experiments were performed 
for at least three times. Values represent means ± SEM. 
*P < 0.05, **P < 0.01, ***P < 0.001.
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